Rostafuroxin: An ouabain antagonist that corrects renal and vascular Na +-K +-ATPase alterations in ouabain and adducin-dependent hypertension

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 290, Issue 3, 2006, Pages

  Ferrari, Patrizia ^a,b   Ferrandi, Mara ^a,b   Valentini, Giovanni ^a,b   Bianchi, Giuseppe ^c  

^a Prassis Sigma Tau Research Institute   (Italy)

^b Medical Department Research and Development Division   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Adducin; Antihypertensive therapy; Endogenous ouabain; Na + k + pump

Indexed keywords

17BETA (3 FURYL) 5BETA ANDROSTANE 3BETA,14BETA,17ALPHA TRIOL; ADDUCIN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); EPIDERMAL GROWTH FACTOR RECEPTOR; 17 (3 FURYL) 5BETA ANDROSTANE 3,14,17 TRIOL; 17-(3-FURYL)-5BETA-ANDROSTANE-3,14,17-TRIOL; ANDROSTANE DERIVATIVE; ANTIHYPERTENSIVE AGENT; CALMODULIN BINDING PROTEIN; OUABAIN;

ANTIHYPERTENSIVE THERAPY; DRUG EFFICACY; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; ESSENTIAL HYPERTENSION; EXPERIMENTAL MODEL; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SODIUM ABSORPTION; SODIUM TRANSPORT; VASCULARIZATION; ANIMAL; BLOOD VESSEL; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY; METABOLISM; TREATMENT OUTCOME;

ANDROSTANOLS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD VESSELS; CALMODULIN-BINDING PROTEINS; HUMANS; HYPERTENSION; KIDNEY; NA(+)-K(+)-EXCHANGING ATPASE; OUABAIN; TREATMENT OUTCOME;

EID: 33645397436     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00518.2005     Document Type: Review

References (60)

1. Bagrov A, Fedorova O, Maslova M, Roukoyatkina NI, Ukhanova M, and Zhao EP. Endogenous plasma Na-K ATPase inhibitory activity and digoxin-like immunoreactivity after acute myocardial infarction. Cardiovasc Res 25: 371-377, 1991.
2. Berlowitz DR, Ash AA, Hichey EC, Friedman RH, Glickman M, Kader B, and Moskowitz MA. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 339: 1957-1963, 1998.
3. Bianchi G, Fox U, Di Francesco GF, Giovanetti AM, and Pagetti D. Blood pressure changes produced by kidney cross-transplantation between spontaneously hypertensive rats and normotensive rats. Clin Sci Mol Med 47: 435-448, 1974.
4. Bianchi G, Tripodi G, Casari G, Salardi S, Barber BR, Garcia R, Leoni P, Torielli L, Cusi D, Ferrandi M, Pinna LA, Baralle FE, and Ferrari P. Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 91: 3999-4003, 1994.
5. Bianchi G, Staessen JA, and Ferrari P. Pharmacogenomics of primary hypertension - the lessons from the past to look toward the future. Pharmacogenomics 4: 279-296, 2003.
6. Bianchi G, Ferrari P, and Staessen JA. Adducin polymorphism detection and impact on hypertension and related disorders. Hypertension 45: 331-340, 2005.
7. Bianchi G. The Starling Lecture. Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms. Am J Physiol Regul Integr Comp Physiol 289: R1536-R1549, 2005.
8. Brownie A. The adrenal cortex in hypertension: DOCA/salt hypertension and beyond. In: Hypertension: Pathophysiology, Diagnosis and Management, edited by Laragh JH and Brenner BM. New York: Raven, 1990, chapt. 5, p. 63.
9. Casari G, Barlassina C, Cusi D, Zagato L, Muirhead R, Righetti M, Nembri P, Amar K, Gatti M, Macciardi F, Binelli G, and Bianchi G. Association of the alpha-adducin locus with essential hypertension. Hypertension 25: 320-326, 1995.
10. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, and Bianchi G. Polymorphism of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 349: 1353-1357, 1997.
11. Delva P, Devynck MA, Degan M, Pernollet MG, Carraroli M, Capra C, Steele A, and Lechi A. Plasma levels of an endogenous Na-K pump inhibitor in relation to haemodynamic data in cardiopathic patients. Clin Sci (Lond) 81: 23-29, 1991.
12. Dostanic I, Paul RJ, Lorenz JN, Theriault S, Van Huysse JW, and Lingrel JB. The alpha2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. Am J Physiol Heart Circ Physiol 288: H477-H485, 2005.
13. +-ATPase endocytosis. Circ Res 95: 1100-1108, 2004.
14. Feraille E, Carranza ML, Rousselot M, and Favre H. Modulation of Na+,K+-ATPase activity by a tyrosin phosphorylation process in rat proximal convoluted tubule. J Physiol 498: 99-108, 1997.
15. Ferrandi M, Minotti E, Salardi S, Florio M, Bianchi G, and Ferrari P. Ouabain-like factor in Milan hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 263: F739-F748, 1992.
16. Ferrandi M, Tripodi G, Salardi S, Florio M, Modica R, Barassi P, Parenti P, Shainskaya A, Karlish S, Bianchi G, and Ferrari P. Renal Na-K ATPase in genetic hypertension. Hypertension 28: 1018-1025, 1996.
17. Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G, and Ferrari P. Ouabain-like factor quantification in human tissues and plasma: comparison of two independent assays. Hypertension 30: 886-896, 1997.
18. Ferrandi M, Barassi P, Minotti E, Duzzi L, Molinari I, Bianchi G, and Ferrari P. PST 2238: a new antihypertesive compound that modulates renal Na-K pump function without diuretic activity in Milan hypertensive rats. J Cardiovasc Pharmacol 40: 881-889, 2002.
19. Ferrandi M, Molinari I, Barassi P, Minotti E, Bianchi G, and Ferrari P. Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238. J Biol Chem 279: 33,306 -33,314, 2004.
20. Ferrandi M, Manunta P, Ferrari P, and Bianchi G. The endogenous ouabain: molecular basis of its role in hypertension and cardiovascular complications. Front Biosci 10: 2472-2477, 2005.
21. Ferrari P, Cusi D, Barber BR, Barlassina C, Vezzoli G, Duzzi L, Minotti E, and Bianchi G. Erythrocyte membrane and renal function in relation to hypertension in rats of the Milan hypertensive strain. Clin Sci (Lond) 63: 61-64, 1982.
22. Ferrari P and Bianchi G. Lessons from experimental genetic hypertension. In: Hypertension: Pathophysiology, Diagnosis and Management. edited by Laragh JH and Brenner BM. New York: Raven, chapt. 74, p. 126, 1995.
23. Ferrari P, Torielli L, Ferrandi M, Padoani G, Duzzi L, Florio M, Conti F, Melloni P, Vesci L, Corsico N, and Bianchi G. PST 2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J Pharmacol Exp Ther 285: 83-94, 1998.
24. Ferrari P, Ferrandi M, Torielli L, Tripodi MG, Melloni P, and Bianchi G. PST 2238: a new antihypertensive compound that modulates Na-K ATPase and antagonizes the pressor effect of OLF. Cardiovasc Drug Rev 17: 39-57, 1999.
25. Ferrari P, Ferrandi M, Tripodi G, Torielli G, Padoani G, Minotti E, Melloni P, and Bianchi G. PST 2238: a new antihypertensive compound that modulates Na-K ATPase in genetic hypertension. J Pharmacol Exp Ther 288: 1074-1083, 1999.
26. Glorioso N, Filigheddu F, Cusi D, Troffa C, Conti M, Natalizio M, Argiolas G, Barlassina C, and Bianchi G. alpha-Adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. Hypertension 39: 357-362, 2002.
27. Goto A, Yamada K, Nagoshi H, Dan Y, and Omata M. Role of the ouabain-like compound in the regulation of transmembrane sodium and potassium gradients in rats. Hypertension 30: 753-758, 1997.
28. Goto A and Yamada K. An approach to the development of novel antihypertensive drugs: potential role of sodium pump inhibitors. Trends Pharmacol Sci 19: 201-204, 1998.
29. Gottlieb SS, Rogowski A, Weinberg M, Krichten CM, Hamilton BP, and Hamlyn JM. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 86: 420-425, 1992.
30. Graves SW, Lincoln K, Cook SL, and Seely EW. Digitalis-like factor and digoxin-like immunoreactive factor in diabetic women with preeclampsia, transient hypertension of pregnancy, and normotensive pregnancy. Am J Hypertens 8: 5-11, 1995.
31. Haas M, Askari A, and Xie Z. Involvement of Src and epidermal growth factor receptor in the signal-transducing function of Na+/K+-ATPase. J Biol Chem 275: 27832-27837, 2000.
32. Hamlyn JM, Ringel R, Schaffer J, Levinson PD, Hamilton BP, Kowarski AA, and Blaustein MP. A circulating inhibitor of the Na-K ATPase associated with essential hypertension. Nature 300: 650-652, 1982.
33. Hamlyn JM, Lu Z, Manunta P, Ludens JH, Kimura K, Shah J, Laredo J, Hamilton J, Hamilton M, and Hamilton B. Observations on the nature, biosynthesis, secretion and significance of endogenous ouabain. Clin Exp Hypertens 20: 523-533, 1998.
34. Horan MJ and Mockrin SC. Heterogeneity of hypertension. Am J Hypertens 5: 110S-113S, 1992.
35. 2+ exchanger type-1 in vascular smooth muscle. Nat Med 10: 1193-1199, 2004.
36. Kimura K, Manunta P, Hamilton BP, and Hamlyn JM. Different effects of in vivo ouabain and digoxin on renal artery function and blood pressure in the rat. Hypertens Res 23: S67-S76, 2000.
37. Kojima I, Yoshihara S, and Ogata E. Involvement of endogenous digitalis-like substance in genesis of deoxycorticosterone-salt hypertension. Life Sci 30: 1775-1781, 1982.
38. Lifton RP. Molecular genetics of human blood pressure variation. Science 272: 676-680, 1996.
39. 2+ concentrations. J Biol Chem 275: 27838-27844, 2000.
40. Manunta P, Rogowski AC, Hamilton BP, and Hamlyn JM. Ouabain-induced hypertension in the rat: relationships among circulating and tissue ouabain and blood pressure. J Hypertens 12: 549-560, 1994.
41. Manunta P, Stella P, Rivera R, Ciurlino D, Cusi D, Ferrandi M, Hamlyn JM, and Bianchi G. Left ventricular mass, stroke volume and ouabain-Like factor in essential hypertension. Hypertension 34: 450-456, 1999.
42. Manunta P, Messaggio E, Ballabeni C, Sciarrone MT, Lanzani C, Ferrandi M, Hamlyn JM, Cusi D, Galletti F, and Bianchi G. Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 38: 198-203, 2001.
43. Manunta P, Iacoviello M, Forleo C, Messaggio E, Hamlyn JM, Lucarelli K, Guida P, Romito R, De Tommasi E, Bianchi G, Rizzon P, and Pitzalis MV. High circulating levels of endogenous ouabain in the offspring of hypertensive and normotensive individuals. J Hypertens 23: 1677-1681, 2005.
44. Menard J, Bellet M, and Serrurier D. From the parallel group study to the crossover design, and from the group approach to the individual approach. Am J Hypertens 3: 815-819, 1990.
45. Moreth K, Renner D, and Schoner W. A quantitative receptor assay for digitalis-like compounds in serum: demonstration of raised concentrations in essential hypertension and correlation with arterial pressure. Klin Wochenschr 65: 179-184, 1987.
46. Murrell JR, Randall JD, Rosoff J, Zhao J, Jensen RV, Gullans SR, and Haupert GT. Endogenous ouabain: upregulation of steroidogenic genes in hypertensive hypothalamus but not adrenal. Circulation 112: 1301-1308, 2005.
47. Pamnani MB, Burris JF, Jemionek JF, Huot SJ, Price M, Freis ED, and Haddy FJ. Humoral Na-K pump inhibitor activity in essential hypertension and in normotensive subjects after acute volume expansion. Am J Hypertens 2: 524-531, 1989.
48. Pamnani MB, Withehorn WV, Clough DL, and Haddy FG. Effects of canrenone on blood pressure in rat with reduced renal mass. Am J Hypertens 3: 188-195, 1990.
49. Pierdomenico SD, Bucci A, Manunta P, Rivera R, Ferrandi M, Hamlyn JM, Lapenna D, Cuccurullo F, and Mezzetti A. Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension. Am J Hypertens 14: 44-50, 2001.
50. Pitzalis MV, Hamlyn JM, Messaggio E, Iacoviello M, Forleo C, Romito R, De Tommasi E, Rizzon P, Bianchi G, and Manunta P. Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. Eur J Heart Failure In press.
51. Quadri L, Bianchi G, Cerri A, Fedrizzi G, Ferrari P, Gobbini M, Melloni P, Sputore S, and Torri, M. 17β-(3-Furyl)-5β-androstane-3β, 14β, 17α-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. J Med Chem 40: 1561-1564, 1997.
52. Roman RJ. Abnormal renal hemodynamics and pressure-natriuresis relationship in Dahl salt-sensitive rats. Am J Physiol Renal Fluid Electrolyte Physiol 251: F57-F65, 1986.
53. Rossi GP, Manunta P, Hamlyn J, Pavan E, De Toni R, Semplicini A, and Pessina AC. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: ralationship with plasma renin, aldosterone and blood pressure levels. J Hypertens 13: 1181-1191, 1995.
54. Staessen JA, Kuznetsova T, Acceto R, Bacchieri A, Brand E, Burnier M, Celis H, Citterio L, de Leeuw PW, Filipovsky J, Fournier A, Kawecka-Jaszcz K, Mariunta P, Nikitin Y, O'Brien ET, Redón J, Thijs L, Ferrari P, Valentini G, Bianchi G, on behalf of the OASIS-IT Investigators. Ouabain and adducin for specific intervention on sodium in hypertension (OASIS-HT): design of a pharmacogenomic dose-finding study. Pharmacogenomics 6: 755-775, 2005.
55. Takada T, Nakagawa M, Ura N, Kaide J, Yoshida H, and Shimamoto K. Endogenous immunoreactive ouabain-like and digoxin-like factors in reduced renal mass hypertensive rats. Hypertens Res 21: 193-199, 1998.
56. Toka HR and Luft FC. Monogenic forms of human hypertension. Semin Nephrol 22: 81-88, 2002.
57. Tripodi G, Valtorta F, Torielli L, Chieregatti E, Salardi S, Trusolino L, Menegon A, Ferrari P, Marchisio PC, and Bianchi G. Hypertension - associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J Clin Invest 97: 2815-2822, 1996.
58. Tripodi MG, Florio M, Ferrandi M, Modica R, Zimdahl H, Hubner N, Ferrari P, and Bianchi G. Effect of add1 gene transfer on blood pressure in reciprocal congenic strains of Milan Rats. Biochem Biophys Res Commun 324: 562-568, 2004.
59. Weinehall L, Ohgren B, Persson M, Stegmayr B, Boman K, Hallmans G, and Lindholm LH. High remaining risk in poorly treated hypertension: the 'rule of halves' still exists. J Hypertens 20: 2081-2088, 2002.
60. Zhang J, Lee MY, Cavalli M, Chen L, Berra-Romani R, Balke WC, Bianchi G, Ferrari P, Hamlyn JM, Iwamoto T, Lingrel JB, Matteson DR, Gil Wier E, and Blaustein MP. Sodium pump α2 subunits control myogenic tone and blood pressure in mice. J Physiol In press.